No Data
No Data
Insider Sale: CHIEF FINANCIAL OFFICER of $ELVN (ELVN) Sells 900 Shares
Clear Street Launches Healthcare & Biotechnology Equity Research
We're Hopeful That Enliven Therapeutics (NASDAQ:ELVN) Will Use Its Cash Wisely
BTIG Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $42
Enliven Therapeutics' ELVN-001: Navigating Competitive Challenges and Opportunities in the CML Market
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38
Unlock the Full List